Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

Zenopa was extremely helpful in identifying the right opportunity for me when I was looking to take my career to the next level.
Shreena , 2014

Pfizer receives new regulatory approval for Prevnar 13

3 January 2012 00:00 in Pharmaceutical Company Product News

Pfizer has received a positive regulatory decision from the US Food and Drug Administration (FDA) on its pneumococcal conjugate vaccine Prevnar 13.

The treatment has been ratified as a single-dose treatment for adults aged over 50 against pneumonia and invasive disease caused by 13 common Streptococcus pneumoniae serotypes, as well as for use in active immunisation programmes.

Prevnar 13 has demonstrated its safety and efficacy in phase III studies conducted among more than 6,000 patients, during which it was shown to deliver a strong functional antibody response.

Currently, the drug is approved in the EU, Australia, Mexico and more than ten other nations in addition to the US.

Ian Read, chairman and chief executive officer at Pfizer, said: "This approval is representative of Pfizer's dedication to discovering and bringing to market life-changing medicines and vaccines."

This comes after the company published positive clinical trial data last month showing the efficacy of its overactive bladder treatment Toviaz among elderly patients.ADNFCR-8000103-ID-801253252-ADNFCR

Other news stories from 03/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd